



Medication for Addiction Treatment

Reimbursement Policy

Purpose

To provide guidance on claim submission for behavioral health: medication-assisted treatment (MAT)-methadone, buprenorphine, and naltrexone for opioid use disorder (OUD) within the provider's scope of practice as defined by the provider's licensing board.

Definitions

Medication for Addiction Treatment (MAT): (also known as Medication-Assisted Treatment) is the use of medications, with the use of psychosocial therapies and supports as needed, to provide a whole-person approach to the treatment of substance use disorders.

Opioid Treatment Programs (OTPs): programs certified by the United States Substance Abuse and Mental Health Services Administration (SAMHSA) that engage in supervised assessment and treatment, using methadone, buprenorphine, or naltrexone, of members who have an OUD. OTP includes the use of medication for opioid use disorder (MOUD) in addition to the psychotherapy services to treat a member with an OUD. Members must have primary OUD to be treated at an OTP.

Office-Based Addiction Treatment (OBAT) Providers: previously known as "office-based opioid treatment (OBOT)", deliver addiction treatment services to members with OUD as well as other primary substance use disorders (SUD). Preferred OBAT services are required to be provided by buprenorphine-waivered practitioners working in collaboration and co-located with Credentialed Addiction Treatment Professionals providing psychosocial treatment in public and private practice settings.

Policy

Methadone

HCPCS H codes were established for use by state Medicaid agencies to set specific guidelines for their reporting and use for claim submission.

Community Health Options follows the Maine Medicaid program (MaineCare) claim submission rules for methadone treatment (or its equivalent). Those rules are available within the MaineCare Benefits Manual, and the billing guidelines set forth herein are specific to the state of Maine, as billing guidelines vary by state from which the plan resides.

Methadone treatment is required to be billed on a CMS-1500 claim form under the HCPCS code of H0020. H0020 is a weekly code billed with one unit. According to the Department of Health & Human Services (DHHS), billing guidelines are to use the date range of Sunday through Saturday for the weekly charge. Billing outside these guidelines may lead to claim denials.

HCPCS	Long Description	Frequency	Unit(s)
H0020	Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program)	Weekly	1

Office-Based Addiction Treatment (OBAT) vs. Licensed Opioid Treatment Programs (OTPs)

Office-based addiction treatment (OBAT) refers to outpatient treatment services provided in settings other than licensed Opioid Treatment Programs (OTPs). OBAT is provided by DATA 2000-waivered clinicians for patients with OUD. For a patient, an OBAT visit is a chronic disease visit and includes a meeting with a clinician, a prescription for buprenorphine or naltrexone, and other medical and psychosocial interventions and support with markers of recovery to achieve and sustain remission. OBATs differ from OTPs (also known as a Methadone Clinic or Methadone Maintenance Treatment Program), which are the only settings in the U.S. that can prescribe methadone for OUD. Unlike OBAT settings, U.S. OTPs must be certified by the Center for Substance Abuse Treatment (CSAT), a division of HHS-SAMHSA. OTPs operate under the supervision of a physician and provide counseling and other recovery supports along with medical services related to dosing and treatments on site, which usually require daily visits to the clinic. OBAT programs, however, are provided by clinicians within their regular medical practice. This setting can help expand access to treatment and provide a more private experience for the patient with opioid use disorder. In the U.S. today, OBAT uses the medications buprenorphine and/or naltrexone. OBAT programs have fewer requirements and regulations placed on the patient, which can allow easier access to treatment. For example, OBAT may have daily dosing on site, if needed, but dosing usually occurs within the patient's home and usually is not witnessed by a medical professional. There also is a limit to the number of patients an OBAT clinician may treat.

Office-Based Addiction Treatment Billing

The following HCPCS codes are for contracted facilities for such services.

HCPCS	Description
G2086	In the first calendar month: <ul style="list-style-type: none"> Developed the treatment plan Coordinated care Provided at least 70 minutes of individual therapy and group therapy and counseling
G2087	In a subsequent calendar month: <ul style="list-style-type: none"> Coordinated care Provided at least 60 minutes of individual therapy and group therapy and counseling
G2088	<ul style="list-style-type: none"> Coordinated care Provided more than 120 minutes of therapy and counseling Note: Bill each additional 30 minutes separately and include the code for the primary procedure

Licensed Opioid Treatment Programs Billing

The following HCPCS codes are for contracted facilities for such services.

HCPCS	Description
-------	-------------

G2067	Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)
G2068	Medication assisted treatment, buprenorphine (oral); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)
G2069	Medication assisted treatment, buprenorphine (injectable); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)
G2070	Medication assisted treatment, buprenorphine (implant insertion); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)
G2071	Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)
G2072	Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)
G2073	Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)
G2074	Medication assisted treatment, weekly bundle not including the drug, including substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)
G2075	Medication assisted treatment, medication not otherwise specified; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a Medicare-enrolled Opioid Treatment Program)

Intensity Add-on Codes

HCPCS	Long Description
G2076	Intake activities, including initial medical examination that is a complete, fully documented physical evaluation and initial assessment by a program physician or a primary care physician, or an authorized healthcare professional under the supervision of a program physician or qualified

	personnel that includes preparation of a treatment plan that includes the patient's short-term goals and the tasks the patient must perform to complete the short-term goals; the patient's requirements for education, vocational rehabilitation, and employment; and the medical, psycho-social, economic, legal, or other supportive services that a patient needs, conducted by qualified personnel provision of the services by a Medicare-enrolled Opioid Treatment Program); List separately in addition to code for primary procedure.
G2077	Periodic assessment; assessing periodically by qualified personnel to determine the most appropriate combination of services and treatment (provision of the services by a Medicare-enrolled Opioid Treatment Program); List separately in addition to code for primary procedure.
G2078	Take-home supply of methadone; up to 7 additional day supply (provision of the services by a Medicare-enrolled Opioid Treatment Program); List separately in addition to code for primary procedure.
G2079	Take-home supply of buprenorphine (oral); up to 7 additional day supply (provision of the services by a Medicare-enrolled Opioid Treatment Program); List separately in addition to code for primary procedure.
G2080	Each additional 30 minutes of counseling in a week of medication assisted treatment, (provision of the services by a Medicare-enrolled Opioid Treatment Program); List separately in addition to code for primary procedure.
G2215	Take-home supply of nasal naloxone; 2-pack of 4mg per 0.1 mL nasal spray (provision of the services by a Medicare-enrolled Opioid Treatment Program); List separately in addition to code for primary procedure.
G2216	Take-home supply of injectable naloxone (provision of the services by a Medicare-enrolled Opioid Treatment Program); List separately in addition to code for primary procedure.
G1028	Take-home supply of nasal naloxone; 2-pack of 8mg per 0.1 mL nasal spray (provision of the services by a Medicare-enrolled Opioid Treatment Program); List separately in addition to code for primary procedure.)

References/Resources

Centers for Medicare & Medicaid Services (2020, October 13). *Office-Based Opioid Use Disorder (OUD) Treatment Billing*. Retrieved from <https://www.cms.gov/medicare/physician-fee-schedule/office-based-opioid-use-disorder-oud-treatment-billing>

Centers for Medicare and Medicaid Services (2021, November). *Opioid Treatment Programs (OTPs) Medicare Billing & Payment*. Retrieved from <https://www.cms.gov/files/document/otp-billing-and-payment-fact-sheet.pdf>

MaineCare Benefits Manual 10-144, Chapter III-Section 65
<https://www.maine.gov/sos/cec/rules/10/ch101.htm>

Document Publication History

9/21/2023 Annual Review: replaced Medication-Assisted Treatment with Medication for Addiction Treatment and added definition
10/21/2022 Added sections for OTPs and OBAT
04/12/2022 Annual Review: minor administrative updates
04/21/2021 Initial publication

This policy provides information on Community Health Options' claims adjudication processing guidelines. As every claim is unique, the use of this policy is neither a guarantee of payment nor a final prediction of how specific claim(s) will be adjudicated. Claims payment is subject to member eligibility and benefits on the date of service, coordination of benefits, referral/authorization, and utilization management guidelines when applicable, adherence to plan policies and procedures, and claims editing logic. Community Health Options reserves the right to amend a payment policy at its discretion. Policies are enforced unless underpinning direction stated otherwise.